Riskpilot← Back to searchSign inGet full accessBioblik AB
ABActiveOrg 5590576673Botvidsgatan 15Business and other management consultancy activities · NACE 7020Est. 20161 employees
Revenue 2024
SEK 0
EBITDA margin
—
-25% vs 2023
Equity ratio
95.5%
Financial strength
Net profit 2024
SEK -131K
-7106% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -136K | -25% |
| Net profit | SEK -131K | -7106% |
| Total assets | SEK 256K | -34% |
| Equity | SEK 244K | -35% |
| Employees | 1 | — |
Legal name
Bioblik AB
Org number
5590576673
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
6 april 2016
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva konsultverksamhet inom bioteknik, läkemedel och medicin tekniska områden samt förvaltning av finansiella instrument jämte därmed förenlig verksamhet.
Address
Botvidsgatan 15
Email
bioblik@telia.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 332 | 0 | −0 | −0 | 0 |
| Staff expenses | — | — | −15 | −18 | −22 |
| EBITDA | 132 | −149 | −122 | −109 | −136 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 132 | −149 | −122 | −109 | −136 |
| Net financials | — | — | 1 | 7 | 5 |
| Profit before tax | 98 | −149 | 21 | −2 | −131 |
| Tax | −21 | −0 | — | — | — |
| Net profit | 77 | −149 | 21 | −2 | −131 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 061 | 604 | 488 | 387 | 256 |
| Equity | 689 | 356 | 377 | 376 | 244 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 129 | 5 | 11 | 12 | 12 |
| Total debt | 129 | 5 | 11 | 12 | 12 |
EBITDA margin
-13648200.0%
This company
15.8%
Market median
-86381113% vs market
20202024
Equity ratio
95.5%
This company
38.2%
Market median
+150% vs market
20202024
Return on equity
-53.7%
This company
18.4%
Market median
-392% vs market
20202024
Net profit margin
-13114200.0%
This company
8.1%
Market median
-161903804% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
IC Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Bioblik AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ingrid Cornelia Blikstad | Chief Executive Officer | 0 companies |
| Cecilia Maria Elisabeth Blikstad | Deputy Board Member | 0 companies |
| Magnus Oscar Fredrik Blikstad | Deputy Board Member | 0 companies |